Health insurance: Digitally controlled iFOBT tests should increase screening rates

Stuttgart. AOK Baden-Württemberg aims to increase the uptake of colorectal cancer screening using the immunological stool test for invisible blood (iFOBT). To this end, it is collaborating with the provider CKM Group. As the company announced on Tuesday, it aims to make screening simpler, more accessible, and more efficient through a fully digitally integrated screening model. The health insurance company is offering this model to its insured members in addition to the colorectal cancer screening program legally organized by the Federal Joint Committee (G-BA).

The digitally controlled colorectal cancer screening based on the iFOB test combines previously isolated process steps – from eligibility verification and test administration to laboratory analysis and result communication – into a seamless hybrid screening offering. Access is digital: The offering is directly linked to the "My AOK" online portal, and the eligibility check is conducted via the linked landing page. If the result is positive, the insured person receives the test kit by mail. Instructions guide the sample collection, and an integrated reminder system ensures timely return to an accredited laboratory, where the analysis takes place.

The results will be sent either digitally or by mail. A positive result indicates a possible risk of colon cancer. Therefore, insured individuals will receive a recommendation for a diagnostic colonoscopy and a prepared version of the test result for further use by physicians. (eb)